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Abstract 
BACKGROUND: We explored regional brain atrophy patterns and their clinical correlates in 
dementia with Lewy bodies (DLB). 
METHODS: In this multicentre study we included a total of 333 DLB patients, 352 
Alzheimer’s disease (AD) patients, and 233 normal controls and used medial temporal lobe 
atrophy (MTA), posterior atrophy (PA), and frontal atrophy (GCA-F) visual rating scales. 
Patients were classified according to four atrophy patterns. 
RESULTS: DLB had higher scores on all the three atrophy scales as compared to NC, but had 
less MTA than AD (all p-values <0.001). A signature hippocampal-sparing pattern of regional 
atrophy was observed in DLB. The MRI measures showed 65% ability to discriminate between 
DLB and AD, and marginally contributed to the discrimination over and above the core clinical 
features.  
CONCLUSION: The most common pattern of atrophy of DLB was hippocampal-sparing. 
Future studies should explore whether comorbid AD pathology underlies the atrophy patterns 
seen in DLB. 
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1 Background 
Differentiating between dementia types continues to be challenging due the clinico-
pathological overlap between neurodegenerative diseases [1], but is important for optimal 
patient care [2]. Misfolding and aggregation of the same proteins are common across different 
clinical phenotypes, and vice-versa, the same clinical phenotype may result from different 
misfolded proteins [3]. For instance, amyloid-beta (Aβ) plaques, the main pathophysiological 
hallmark of Alzheimer’s disease (AD), are commonly found in dementia with Lewy bodies 
(DLB); and alpha (α)-synuclein inclusions, the key pathology in DLB, are often seen in AD 
brains [4]. In addition, the spatial distribution of misfolded proteins can vary within the same 
disease, leading to distinct disease subtypes. [5-7]. Clinical and pathological heterogeneity is 
also common in DLB, such as the degree of AD-type pathology [8], which influences the 
clinical presentation, progression, and response to treatment [9, 10]. Thus, improving 
differential diagnosis between neurodegenerative diseases is important in order to provide 
optimal patient care and better predict future needs. 
 
Structural magnetic resonance imaging (sMRI) is a powerful means to improve differential 
diagnosis and unravel disease heterogeneity [11]. Patterns of brain atrophy in sMRI can reliably 
track the spread of neurofibrillary tangles (NFT) [7] and easily be translated to the clinical 
routine by assessing brain atrophy with visual rating scales [5]. These visual rating scales are 
quick and easy to use and are the primary method for assessing brain structural changes in a 
clinical setting [12, 13]. Atrophy in the medial temporal lobe, commonly measured with the 
medial temporal atrophy (MTA) scale [14, 15], is included in the current diagnostic criteria for 
AD [16, 17]. Conversely, preserved medial temporal lobe volume is listed as a supportive 
biomarker of DLB [18]. However, MTA does occur in DLB [19], which would detract from 
the usefulness of this marker in individual cases [20]. Combining the MTA scale with scales of 
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frontal and posterior brain atrophy may improve their diagnostic capacity [13, 21]. However, 
this has rarely been explored in DLB. The few sMRI studies in DLB usually include small 
samples (normally around 20 individuals), leading to inconsistent results. [22-24]. Thus, 
investigating brain atrophy in DLB in a large cohort, combining MTA with scales of frontal 
and posterior brain atrophy, is urgently needed in DLB.  
 
This retrospective study capitalizes on the European DLB consortium, which includes more 
than 1000 DLB patients, one of the largest DLB cohorts worldwide [25]. The aims of the study 
were to explore 1) the regional brain atrophy pattern in DLB using clinically useful visual rating 
scales, 2) the ability of sMRI to discriminate between DLB and AD, and 3) the clinical 
correlates of MRI atrophy patterns in DLB. 
 
2 Material and Methods  
2.1 Case selection  
The patients were referrals to 15 outpatient memory-, movement disorders-, geriatric medicine-
, psychiatric-, and neurology clinics in Europe. We included patients with DLB, AD and normal 
elderly control subjects (NC) who had MRI scan available for analysis. In addition, we included 
scans of AD and NC from ADNI (http://adni.loni.usc.edu/, PI Michael M. Weiner) [26, 27]. 
The ADNI is a multi-center study from the United States and Canada that was established to 
develop standardized imaging techniques and biomarkers in AD research. ADNI was launched 
in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and 
Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and 
non-profit organizations. The number of participants and source are shown in Table C1 in 
Appendix C. 
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2.2 Diagnostic and clinical examination 
As previously described for E-DLB [25], diagnoses were made according to the 2005 
international consensus criteria for probable DLB [28], and standard diagnostic criteria for AD. 
Diagnosis was done by the treating physician, a group of at least two expert clinicians, or by a 
multidisciplinary team at a consensus diagnostic meeting based on all available clinical and 
diagnostic test data. Diagnostic criteria and procedures for ADNI are described in [26]. 
 
Per design, the procedures were not harmonized across centers, but a detailed history and 
clinical examinations including physical, neurological, and psychiatric examination, were 
performed by a licensed specialist. Centers were requested to record whether patients fulfilled 
criteria for parkinsonism, visual hallucinations, and fluctuating cognition as specified in the 
consensus criteria [28], based on all available information. Routine blood tests were performed. 
Dopamine transporter SPECT (DAT) scan was available to support the diagnosis in 
approximately one third of the DLB patients, and pathological confirmation in a minority. 
Cognitive screening was performed using the MMSE [29]. MRI was used for unstructured 
radiological assessment to exclude other causes for dementia but the visual rating scales were 
not part of the clinical diagnosis. Hence, some results in this study should be considered in the 
context of circularity, especially those related to MMSE and the core clinical features.  
 
Patients with acute delirium, terminal illness, previous stroke, psychotic or bipolar disorder, 
craniocerebral trauma, or recently diagnosed with a major somatic illness were excluded from 
the current study.  
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2.3 Ethics 
Local ethics committee at the individual centre approved data collection for research and the 
inclusion of data in this multicentre study. The patients gave their written consent to use the 
unidentified results of their clinical, instrumental, and laboratory investigations for research 
purposes. 
 
2.4 MRI acquisition and visual rating scales 
Various MRI scanners and protocols were used as detailed in Appendix A.  
All scans were rated by an experienced radiologist (L.C.) who was blind to any clinical 
information including diagnosis. The rater has previously demonstrated excellent intra-rater 
reliability in 120 random cases: weighted  of 0.94 and 0.89 for MTA in left and right 
hemispheres, respectively, 0.88 for PA, and 0.83 for GCA-F [5]. 
 
Regional atrophy was assessed with three visual rating scales based on T1-weigthed images as 
detailed elsewhere [21]. Briefly, atrophy in the medial temporal lobe was evaluated with the 
MTA scale [14]; atrophy in the posterior cortex was evaluated with the posterior atrophy (PA) 
scale [30]; and atrophy in the frontal lobe was evaluated with the global cortical atrophy scale 
– frontal subscale (GCA-F) [31]. The MTA scale scores the degree of atrophy from zero to four 
in the hippocampus, parahippocampal gyrus, entorhinal cortex, and the surrounding 
cerebrospinal fluid spaces. The PA scale scores the degree of atrophy from zero to three in the 
posterior cingulate sulcus, precuneus, parieto-occipital sulcus and the parietal cortex. The 
GCA-F scale scores the degree of atrophy from zero to three in the frontal lobe as delimited by 
the central sulcus, the frontal bone, and the fissure of Sylvius. In the three visual rating scales, 
a score of zero denotes no atrophy, whereas scores from one to three/four indicate an increasing 
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degree of atrophy. MTA analysis was based on coronal reconstructions, GCA-F on axial 
reconstructions, and PA on reconstructions from all three planes.  
 
Patterns of atrophy were investigated by combining the scores from MTA, GCA-F, and PA. 
Each case was classified according to our previously described system [5] giving four distinct 
atrophy patterns: Typical AD, limbic-predominant AD, hippocampal-sparing AD, and 
minimal-atrophy AD. Typical AD was defined as abnormal MTA together with abnormal PA 
and/or abnormal GCA-F. Limbic-predominant was defined as abnormal MTA alone with 
normal PA and GCA-F. Hippocampal-sparing included abnormal PA and/or abnormal GCA-
F, but normal MTA. Minimal atrophy AD was defined as normal scores in MTA, PA, and 
GCA-F. Deviation from normality was established following previously published cut-offs 
[21]. The MTA scores ≥1.5, ≥1.5, ≥2, ≥2.5 were considered abnormal for the respective age 
ranges 45–64, 65–74, 75–84, and 85–94 years. Since an age-correction does not improve PA 
and GCA-F diagnostic performance, a score ≥1 was considered abnormal irrespectively of the 
age range [21]. More information regarding these subtypes can be found elsewhere [5]. Figure 
D.1 in Appendix D shows visual examples of characteristic cases. 
 
2.5 Statistics 
The main interest in this study was the potential differences between DLB and NC, as well as 
between DLB and AD. Thus, pair-wise models were conducted as described below and in 
Appendix B, including all the variables of interest to investigate their effect simultaneously and 
reducing the number of comparisons [32]. A third pair-wise model for the comparison between 
AD and NC is also reported for completeness of information. All the p-values reported are two-
sided and were considered significant when 0.05. Further, p-values were adjusted with the 
Hochberg’s correction for multiple testing as stated in the results section [33]  
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The demographic and clinical data were pair-wise compared across the study groups using 
logistic regression. Diagnosis was included as the Y variable and age, sex, education, and 
MMSE, as the predictors. The associations of these variables with the visual rating scales and 
with themselves in the DLB patients are shown in Figure 1. Further details on these analyses 
are provided in the Appendix B. Based on this, we included age and sex as the main 
confounding variables in all the models. Sensitivity analyses were also conducted by including 
education as extra confounding variable (as well as MMSE when comparing the AD and DLB 
groups). 
 
The GCA-F and PA scales were pair-wise compared across the study groups by using ordinal 
regression because of their ordinal nature. The GCA-F and PA ratings were included as Y 
variables, and diagnosis, age, sex, education, and MMSE as predictors in two separate models. 
A similar model using multiple linear regression was conducted for MTA (average of left and 
right). Mixed ANCOVA was used to analyze the interaction between a between-subjects factor 
(diagnosis, 3 levels) and a within-subjects factor (visual rating scale, 3 levels). Age, sex, 
education, and MMSE were included as covariate variables. MTA scores were converted to a 
scale of 0 to 3 in the Mixed ANCOVA to allow comparison with the GCA-F and PA scores. 
Conversion consisted of multiplying MTA scores by a factor of 0.75 [21].  
 
The frequency of each atrophy subtype was compared across the three groups using one-way 
ANOVA. The frequency of the different subtypes was compared within each diagnostic group 
against a random distribution using the Chi square test. The details of stepwise analyses 
performed to investigate how well the visual ratings discriminate between DLB and AD 
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patients, as well as to investigate the association between the visual ratings and the core clinical 
features in the DLB patients are described in Appendix B. 
 
3 Results 
3.1 Cohort characteristics 
There were demographic and clinical differences between the groups (Table 1). The 
associations of these variables with the visual rating scales and with themselves in the DLB 
patients are shown in Figure 1. These differences and associations were therefore adjusted for 
in the analyses. The scores of the three visual rating scales are presented in Table 2. The mixed 
ANCOVA showed a significant interaction between study group (DLB vs. AD vs. NC) and 
visual rating scale (MTA vs. GCA-F vs. PA) (F(4, 1583)=20.148; p<0.001) (age and sex included 
as covariate variables) (Figure 2a). The DLB group had significantly more atrophy on all rating 
scales compared to the NC (all p-values <0.001). Compared to AD, DLB had less MTA 
(p<0.001), but the groups did not differ significantly in GCA-F and PA scores. We observed a 
significantly higher overall atrophy in AD (p<0.001) (Figure 2b). As described above, this 
effect was explained by the higher MTA score in AD. All the results reported in this paragraph 
remained largely the same when including education and MMSE (when comparing DLB vs. 
AD) in subsequent sensitivity analysis (data not shown). 
 
3.2 Distribution of AD atrophy patterns 
The distribution of the AD atrophy patterns differed between the groups, and also varied 
considerably within groups (Table 3). As expected most NC cases were classified in the 
“minimal-atrophy” group. Compared to the AD group, the DLB group included a lower 
proportion of “typical AD” and “limbic-predominant”, but a larger proportion of “hippocampal-
sparing” and “minimal-atrophy”. Since hippocampal-sparing can include only posterior atrophy 
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(abnormal PA scores), only frontal atrophy (abnormal GCA-F scores), or both, we further 
explored the distribution of abnormal PA and GCA-F scores within the hippocampal-sparing 
pattern. The most contributing region to hippocampal-sparing was the posterior cortex, 
especially in the NC group. However, concurrent abnormal scores in both the PA and GCA-F 
scales were also frequent in DLB and AD, as compared with the NC (p=0.001 and p=0.026, 
respectively). Controlling for the covariates did not change this result. 
 
3.3 Using visual rating scales to discriminate between DLB and AD 
For all the analyses in this section, visual rating scores were dichotomized into normal (0) or 
abnormal (1) according to previously published cut-offs [21]. Table 4 shows the discriminative 
performance of several analyses conducted in a stepwise manner. MTA alone discriminated 
between DLB and AD with an accuracy of 64.7%. Including age, sex, and MMSE in a random 
forest model to control for their potential confounding effect did not modify this result 
substantially (accuracy = 60.7%). We then conducted another random forest model including 
GCA-F and PA in addition to MTA, age, sex, and MMSE. This model marginally increased the 
discriminative performance (accuracy = 65.8%) (Table 4). 
 
The three visual rating scales combined with the DLB core clinical symptoms (and age, sex, 
and MMSE) in a new random forest model, achieved an accuracy of 90.4% to discriminate 
between DLB and AD, compared to 88.7% based on the core feature alone. MTA was the third 
variable in terms of importance, after parkinsonism and visual hallucinations, but before 
cognitive fluctuations (Table 4). Thus, MTA marginally improved discrimination beyond that 
provided by the clinical features of DLB alone. In particular, MTA made a major contribution 
in atypical DLB cases without parkinsonism and visual hallucinations, where a normal MTA 
score was able to rule in most of the DLB patients with such a profile (9 out of 11 DLB patients). 
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Using the atrophy patterns instead of the visual rating scales revealed comparable results and 
highlighted the importance of the hippocampal-sparing pattern. This means that a normal MTA 
score is important, but in combination with abnormal PA and/or GCA-F scores it is even more 
important (Table 4). Similar results were obtained when these models were repeated by 
including education as extra predictive variable (data not shown). 
 
3.4 Association between visual rating scales and core clinical features in DLB 
Among DLB patients with clinical information available (n = 275), 77.2% had parkinsonism, 
58.5% had visual hallucinations, and 84.7% had cognitive fluctuations. For the following 
analyses, visual rating scores were dichotomized into normal (0) or abnormal (1) according to 
previously published cut-offs [21]. MTA was associated with a lower MMSE score (r=-0.145, 
p= 0.008). No significant associations were observed between GCA-F and PA and the MMSE 
score, nor for the three visual rating scales with any of the three DLB core clinical features (data 
not shown). 
 
All analyses were repeated including only those 94 DLB patients with abnormal DAT-scan. 
The results were similar to those in the total group, and several of them became more 
pronounced (data not shown). 
 
4 Discussion 
Establishing the signature pattern of brain atrophy in DLB has the potential to improve 
diagnosis, prediction of clinical course, and treatment response. The main novelty of this 
multicenter study is the first-time investigation of four distinct brain atrophy patterns in DLB 
patients, and its comparison with the distribution seen in AD. As a consequence, we have 
identified the signature atrophy pattern of DLB in the largest cohort reported to date. Although 
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we found widespread atrophy across medial temporal, frontal, and parietal lobes as compared 
to controls, DLB patients had less overall atrophy than the AD patients. In particular, DLB had 
less MTA than AD, but still showed PA and GCA-F atrophy, which indicates a higher 
frequency of the hippocampal-sparing pattern as compared to AD. Thus, the signature pattern 
of brain atrophy in DLB is hippocampal-sparing. Further, we also observed that MRI 
marginally improves the discrimination between DLB and AD over and above that of the core 
clinical features alone. In particular, MRI had greatest importance when discriminating atypical 
DLB cases without parkinsonism and visual hallucinations. 
 
Relative preservation of medial temporal lobe is listed as a “supportive biomarker” in the 
recently revised diagnostic criteria for DLB [18]. MTA alone could discriminate between DLB 
and AD with 64.7% accuracy, and contributed to the classification together with the core 
clinical features. However, a novel contribution of our study to the revised diagnostic criteria 
for DLB is that, indeed, lack of MTA is important, but more important is lack of MTA with the 
presence of atrophy in the posterior cortex (and/or the frontal cortex). This is by definition the 
hippocampal-sparing pattern. Thus, we suggest that relative preservation of medial temporal 
lobes concurrent with a marked PA and/or GCA-F supports the diagnosis of DLB, especially 
in cases showing inconsistent or absent core clinical features. The clinical utility of this finding 
should be explored in future studies and perhaps encourage a refinement of the MRI criteria in 
the current diagnostic criteria for DLB [18]. In particular, the clinical discrimination between 
DLB and AD patients with a hippocampal-sparing pattern needs to be further explored. 
 
The emergence of the hippocampal-sparing pattern in our study also aligns with another 
relevant functional biomarker of DLB, i.e. the cingulate island sign and occipital hypoperfusion 
on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). The cingulate island 
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sign reflects sparing of the posterior cingulate cortex relative to the precuneus and cuneus [34]. 
Combining MRI and FDG-PET findings could potentially increase the accuracy of DLB 
diagnosis.  
 
There is a remarkable pathological heterogeneity in DLB. Most DLB patients have some degree 
of AD pathology, which varies from sparse to severe [8]. MTA is associated with degree of tau 
pathology [35], thus more MTA can be seen as a proxy of AD [34]. This interpretation aligns 
with the data from Whitwell et al. [7], where 42% of the AD patients with a hippocampal-
sparing pattern had DLB pathology, while only 30% of those with a typical AD or a limbic-
predominant pattern had DLB pathology. Based on CSF analyses, AD pathology in DLB is 
associated with a more AD-like clinical phenotype [10], more rapid progression of dementia 
[36], and less response to cholinesterase inhibitors [9]. Thus, in addition to aiding in the 
differential diagnosis, the MRI atrophy pattern may provide information regarding the future 
rate of decline, which has been demonstrated in AD patients [5]. However, there are at present 
only few longitudinal DLB studies, with small samples. Thus, investigating AD pathology in 
DLB patterns of atrophy is warranted. 
 
We observed less overall structural atrophy in DLB compared to AD, with similar dementia 
severity. This suggests that functional brain changes, which are potentially reversible and 
amenable to drug therapy, may be more important in DLB compared to AD. For example, 
relatively more and earlier cholinergic deficits have been reported in DLB compared to AD 
[37], which could lead to better response to cholinergic agents [38].  
 
Relatively little is known about the underlying mechanisms of the core clinical features in DLB. 
We found no significant associations between regional atrophy and the core DLB features. 
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Previous studies conducted in smaller samples suggested that motor symptoms are associated 
with nigrostriatal pathology [39, 40]. A recent longitudinal study found that progression of 
parkinsonism was associated with greater whole brain atrophy as well as more hippocampus 
and amygdala atrophy [35]. In our study, MTA was significantly associated with cognitive 
impairment (i.e. lower MMSE score), consistent with previous studies [34]. Visual 
hallucinations have been found to be related to occipital pathology [41], but we did not observe 
any significant association between visual hallucinations and scores in the PA scale. However, 
although one of the criteria of the PA scale is widening of the parieto-occipital sulcus [30], and 
higher scores in the PA scale correlate with less gray matter in the occipital cortex [42], the PA 
scale was not designed to measure atrophy specifically in the occipital lobe. More detailed 
analyses including automated methods for image data processing and analysis, for example 
voxel-based morphometry or cortical thickness studies, may be needed to explore the structural 
brain-correlates of these clinical features. 
 
To our knowledge, this is the largest DLB cohort with MRI scans reported to date. The main 
limitation is the retrospective design, and thus, the diagnostic, clinical, and imaging procedures 
were not harmonized. To overcome the imaging issue, we applied visual rating scales of brain 
atrophy, performed by one rater across all centers, which are robust to variability in scanning 
parameters. Differences in age, sex, education, and MMSE scores were adjusted for throughout 
the statistical analyses. Diagnoses were mainly clinical, with only a subgroup having dopamine 
transporter SPECT and a minority with autopsy studies. Thus, some degree of misdiagnosis 
cannot be excluded, for example, with some DLB patients being diagnosed as AD and vice 
versa. However, these limitations often lead to increased noise, thus reducing the possibility to 
identify small effect sizes and associations. Consistent with this, findings were similar or even 
more pronounced in the DLB subgroup with abnormal DAT scan. Hence, the observed findings 
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in this large cohort are likely robust. However, to improve diagnostic accuracy, future studies 
should aim at including diagnostic markers highly specific for DLB, such as DAT scan, 
metaiodobenzylguanidine scan, and polysomnography [18], and aim towards including a 
substantial subgroup of patients with autopsy-confirmed diagnosis.  Visual rating scales are less 
sensitive than automated methods for image processing and analysis, and are subject to rater 
bias. For this reason, all the scans were rated by a single experienced rater who has previously 
demonstrated high reliability [5]. Furthermore, numerous previous studies have validated 
MTA, PA, and GCA-F against automated imaging methods [31, 42-44], including 
pathologically diagnosed dementia cases [45]. Visual rating scales are simple and quick [12, 
13, 21] and, thus, much more likely to be used in clinical practice, strengthening the real-world 
impact of our findings. Nonetheless, reliable ratings rely on experienced raters, which could 
limit the generalizability of this procedure to centers with less experienced raters. Finally, 
circularity cannot be excluded for MMSE and the core clinical features in this study. MRI was 
visually assessed in an unstructured manner as part of the diagnostic procedure, but is not a core 
feature of DLB and thus was not used for the diagnosis of DLB in this cohort. Since our focus 
was brain atrophy, this issue highlights the discriminative value of MRI when compared to the 
core clinical criteria. With the inclusion of biomarkers as part of the diagnostic criteria for both 
DLB and AD, there will always be a risk for circularity, as previously discussed [12, 51]. 
 
In conclusion, we have shown that DLB patients have widespread cortical atrophy, but 
compared to AD, DLB patients have less overall atrophy following a signature pattern 
consisting of a hippocampal-sparing type. Future studies should explore AD pathological 
comorbidity underlying these atrophy patterns in DLB, apply more detailed measurements of 
cortical and subcortical structures in large DLB cohorts, and explore their ability to predict key 
clinical features. 
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Abstract 
BACKGROUND: We explored regional brain atrophy patterns and their clinical correlates in 
dementia with Lewy bodies (DLB). 
METHODS: In this multicentre study we included a total of 333 DLB patients, 352 
Alzheimer’s disease (AD) patients, and 233 normal controls and used medial temporal lobe 
atrophy (MTA), posterior atrophy (PA), and frontal atrophy (GCA-F) visual rating scales. 
Patients were classified according to four atrophy patterns. 
RESULTS: DLB had higher scores on all the three atrophy scales as compared to NC, but had 
less MTA than AD (all p-values <0.001). A signature hippocampal-sparing pattern of regional 
atrophy was observed in DLB. The MRI measures showed 65% ability to discriminate between 
DLB and AD, and marginally contributed to the discrimination over and above the core clinical 
features.  
CONCLUSION: The most common pattern of atrophy of DLB was hippocampal-sparing. 
Future studies should explore whether comorbid AD pathology underlies the atrophy patterns 
seen in DLB. 
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1 Background 
Differentiating between dementia types continues to be challenging due the clinico-
pathological overlap between neurodegenerative diseases [1], but is important for optimal 
patient care [2]. Misfolding and aggregation of the same proteins are common across different 
clinical phenotypes, and vice-versa, the same clinical phenotype may result from different 
misfolded proteins [3]. For instance, amyloid-beta (Aβ) plaques, the main pathophysiological 
hallmark of Alzheimer’s disease (AD), are commonly found in dementia with Lewy bodies 
(DLB); and alpha (α)-synuclein inclusions, the key pathology in DLB, are often seen in AD 
brains [4]. In addition, the spatial distribution of misfolded proteins can vary within the same 
disease, leading to distinct disease subtypes. [5-7]. Clinical and pathological heterogeneity is 
also common in DLB, such as the degree of AD-type pathology [8], which influences the 
clinical presentation, progression, and response to treatment [9, 10]. Thus, improving 
differential diagnosis between neurodegenerative diseases is important in order to provide 
optimal patient care and better predict future needs. 
 
Structural magnetic resonance imaging (sMRI) is a powerful means to improve differential 
diagnosis and unravel disease heterogeneity [11]. Patterns of brain atrophy in sMRI can reliably 
track the spread of neurofibrillary tangles (NFT) [7] and easily be translated to the clinical 
routine by assessing brain atrophy with visual rating scales [5]. These visual rating scales are 
quick and easy to use and are the primary method for assessing brain structural changes in a 
clinical setting [12, 13]. Atrophy in the medial temporal lobe, commonly measured with the 
medial temporal atrophy (MTA) scale [14, 15], is included in the current diagnostic criteria for 
AD [16, 17]. Conversely, preserved medial temporal lobe volume is listed as a supportive 
biomarker of DLB [18]. However, MTA does occur in DLB [19], which would detract from 
the usefulness of this marker in individual cases [20]. Combining the MTA scale with scales of 
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frontal and posterior brain atrophy may improve their diagnostic capacity [13, 21]. However, 
this has rarely been explored in DLB. The few sMRI studies in DLB usually include small 
samples (normally around 20 individuals), leading to inconsistent results. [22-24]. Thus, 
investigating brain atrophy in DLB in a large cohort, combining MTA with scales of frontal 
and posterior brain atrophy, is urgently needed in DLB.  
 
This retrospective study capitalizes on the European DLB consortium, which includes more 
than 1000 DLB patients, one of the largest DLB cohorts worldwide [25]. The aims of the study 
were to explore 1) the regional brain atrophy pattern in DLB using clinically useful visual rating 
scales, 2) the ability of sMRI to discriminate between DLB and AD, and 3) the clinical 
correlates of MRI atrophy patterns in DLB. 
 
2 Material and Methods  
2.1 Case selection  
The patients were referrals to 15 outpatient memory-, movement disorders-, geriatric medicine-
, psychiatric-, and neurology clinics in Europe. We included patients with DLB, AD and normal 
elderly control subjects (NC) who had MRI scan available for analysis. In addition, we included 
scans of AD and NC from ADNI (http://adni.loni.usc.edu/, PI Michael M. Weiner) [26, 27]. 
The ADNI is a multi-center study from the United States and Canada that was established to 
develop standardized imaging techniques and biomarkers in AD research. ADNI was launched 
in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and 
Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and 
non-profit organizations. The number of participants and source are shown in Table C1 in 
Appendix C. 
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2.2 Diagnostic and clinical examination 
As previously described for E-DLB [25], diagnoses were made according to the 2005 
international consensus criteria for probable DLB [28], and standard diagnostic criteria for AD. 
Diagnosis was done by the treating physician, a group of at least two expert clinicians, or by a 
multidisciplinary team at a consensus diagnostic meeting based on all available clinical and 
diagnostic test data. Diagnostic criteria and procedures for ADNI are described in [26]. 
 
Per design, the procedures were not harmonized across centers, but a detailed history and 
clinical examinations including physical, neurological, and psychiatric examination, were 
performed by a licensed specialist. Centers were requested to record whether patients fulfilled 
criteria for parkinsonism, visual hallucinations, and fluctuating cognition as specified in the 
consensus criteria [28], based on all available information. Routine blood tests were performed. 
Dopamine transporter SPECT (DAT) scan was available to support the diagnosis in 
approximately one third of the DLB patients, and pathological confirmation in a minority. 
Cognitive screening was performed using the MMSE [29]. MRI was used for unstructured 
radiological assessment to exclude other causes for dementia but the visual rating scales were 
not part of the clinical diagnosis. Hence, some results in this study should be considered in the 
context of circularity, especially those related to MMSE and the core clinical features.  
 
Patients with acute delirium, terminal illness, previous stroke, psychotic or bipolar disorder, 
craniocerebral trauma, or recently diagnosed with a major somatic illness were excluded from 
the current study.  
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2.3 Ethics 
Local ethics committee at the individual centre approved data collection for research and the 
inclusion of data in this multicentre study. The patients gave their written consent to use the 
unidentified results of their clinical, instrumental, and laboratory investigations for research 
purposes. 
 
2.4 MRI acquisition and visual rating scales 
Various MRI scanners and protocols were used as detailed in Appendix A.  
All scans were rated by an experienced radiologist (L.C.) who was blind to any clinical 
information including diagnosis. The rater has previously demonstrated excellent intra-rater 
reliability in 120 random cases: weighted  of 0.94 and 0.89 for MTA in left and right 
hemispheres, respectively, 0.88 for PA, and 0.83 for GCA-F [5]. 
 
Regional atrophy was assessed with three visual rating scales based on T1-weigthed images as 
detailed elsewhere [21]. Briefly, atrophy in the medial temporal lobe was evaluated with the 
MTA scale [14]; atrophy in the posterior cortex was evaluated with the posterior atrophy (PA) 
scale [30]; and atrophy in the frontal lobe was evaluated with the global cortical atrophy scale 
– frontal subscale (GCA-F) [31]. The MTA scale scores the degree of atrophy from zero to four 
in the hippocampus, parahippocampal gyrus, entorhinal cortex, and the surrounding 
cerebrospinal fluid spaces. The PA scale scores the degree of atrophy from zero to three in the 
posterior cingulate sulcus, precuneus, parieto-occipital sulcus and the parietal cortex. The 
GCA-F scale scores the degree of atrophy from zero to three in the frontal lobe as delimited by 
the central sulcus, the frontal bone, and the fissure of Sylvius. In the three visual rating scales, 
a score of zero denotes no atrophy, whereas scores from one to three/four indicate an increasing 
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degree of atrophy. MTA analysis was based on coronal reconstructions, GCA-F on axial 
reconstructions, and PA on reconstructions from all three planes.  
 
Patterns of atrophy were investigated by combining the scores from MTA, GCA-F, and PA. 
Each case was classified according to our previously described system [5] giving four distinct 
atrophy patterns: Typical AD, limbic-predominant AD, hippocampal-sparing AD, and 
minimal-atrophy AD. Typical AD was defined as abnormal MTA together with abnormal PA 
and/or abnormal GCA-F. Limbic-predominant was defined as abnormal MTA alone with 
normal PA and GCA-F. Hippocampal-sparing included abnormal PA and/or abnormal GCA-
F, but normal MTA. Minimal atrophy AD was defined as normal scores in MTA, PA, and 
GCA-F. Deviation from normality was established following previously published cut-offs 
[21]. The MTA scores ≥1.5, ≥1.5, ≥2, ≥2.5 were considered abnormal for the respective age 
ranges 45–64, 65–74, 75–84, and 85–94 years. Since an age-correction does not improve PA 
and GCA-F diagnostic performance, a score ≥1 was considered abnormal irrespectively of the 
age range [21]. More information regarding these subtypes can be found elsewhere [5]. Figure 
D.1 in Appendix D shows visual examples of characteristic cases. 
 
2.5 Statistics 
The main interest in this study was the potential differences between DLB and NC, as well as 
between DLB and AD. Thus, pair-wise models were conducted as described below and in 
Appendix B, including all the variables of interest to investigate their effect simultaneously and 
reducing the number of comparisons [32]. A third pair-wise model for the comparison between 
AD and NC is also reported for completeness of information. All the p-values reported are two-
sided and were considered significant when 0.05. Further, p-values were adjusted with the 
Hochberg’s correction for multiple testing as stated in the results section [33]  
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The demographic and clinical data were pair-wise compared across the study groups using 
logistic regression. Diagnosis was included as the Y variable and age, sex, education, and 
MMSE, as the predictors. The associations of these variables with the visual rating scales and 
with themselves in the DLB patients are shown in Figure 1. Further details on these analyses 
are provided in the Appendix B. Based on this, we included age and sex as the main 
confounding variables in all the models. Sensitivity analyses were also conducted by including 
education as extra confounding variable (as well as MMSE when comparing the AD and DLB 
groups). 
 
The GCA-F and PA scales were pair-wise compared across the study groups by using ordinal 
regression because of their ordinal nature. The GCA-F and PA ratings were included as Y 
variables, and diagnosis, age, sex, education, and MMSE as predictors in two separate models. 
A similar model using multiple linear regression was conducted for MTA (average of left and 
right). Mixed ANCOVA was used to analyze the interaction between a between-subjects factor 
(diagnosis, 3 levels) and a within-subjects factor (visual rating scale, 3 levels). Age, sex, 
education, and MMSE were included as covariate variables. MTA scores were converted to a 
scale of 0 to 3 in the Mixed ANCOVA to allow comparison with the GCA-F and PA scores. 
Conversion consisted of multiplying MTA scores by a factor of 0.75 [21].  
 
The frequency of each atrophy subtype was compared across the three groups using one-way 
ANOVA. The frequency of the different subtypes was compared within each diagnostic group 
against a random distribution using the Chi square test. The details of stepwise analyses 
performed to investigate how well the visual ratings discriminate between DLB and AD 
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patients, as well as to investigate the association between the visual ratings and the core clinical 
features in the DLB patients are described in Appendix B. 
 
3 Results 
3.1 Cohort characteristics 
There were demographic and clinical differences between the groups (Table 1). The 
associations of these variables with the visual rating scales and with themselves in the DLB 
patients are shown in Figure 1. These differences and associations were therefore adjusted for 
in the analyses. The scores of the three visual rating scales are presented in Table 2. The mixed 
ANCOVA showed a significant interaction between study group (DLB vs. AD vs. NC) and 
visual rating scale (MTA vs. GCA-F vs. PA) (F(4, 1583)=20.148; p<0.001) (age and sex included 
as covariate variables) (Figure 2a). The DLB group had significantly more atrophy on all rating 
scales compared to the NC (all p-values <0.001). Compared to AD, DLB had less MTA 
(p<0.001), but the groups did not differ significantly in GCA-F and PA scores. We observed a 
significantly higher overall atrophy in AD (p<0.001) (Figure 2b). As described above, this 
effect was explained by the higher MTA score in AD. All the results reported in this paragraph 
remained largely the same when including education and MMSE (when comparing DLB vs. 
AD) in subsequent sensitivity analysis (data not shown). 
 
3.2 Distribution of AD atrophy patterns 
The distribution of the AD atrophy patterns differed between the groups, and also varied 
considerably within groups (Table 3). As expected most NC cases were classified in the 
“minimal-atrophy” group. Compared to the AD group, the DLB group included a lower 
proportion of “typical AD” and “limbic-predominant”, but a larger proportion of “hippocampal-
sparing” and “minimal-atrophy”. Since hippocampal-sparing can include only posterior atrophy 
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(abnormal PA scores), only frontal atrophy (abnormal GCA-F scores), or both, we further 
explored the distribution of abnormal PA and GCA-F scores within the hippocampal-sparing 
pattern. The most contributing region to hippocampal-sparing was the posterior cortex, 
especially in the NC group. However, concurrent abnormal scores in both the PA and GCA-F 
scales were also frequent in DLB and AD, as compared with the NC (p=0.001 and p=0.026, 
respectively). Controlling for the covariates did not change this result. 
 
3.3 Using visual rating scales to discriminate between DLB and AD 
For all the analyses in this section, visual rating scores were dichotomized into normal (0) or 
abnormal (1) according to previously published cut-offs [21]. Table 4 shows the discriminative 
performance of several analyses conducted in a stepwise manner. MTA alone discriminated 
between DLB and AD with an accuracy of 64.7%. Including age, sex, and MMSE in a random 
forest model to control for their potential confounding effect did not modify this result 
substantially (accuracy = 60.7%). We then conducted another random forest model including 
GCA-F and PA in addition to MTA, age, sex, and MMSE. This model marginally increased the 
discriminative performance (accuracy = 65.8%) (Table 4). 
 
The three visual rating scales combined with the DLB core clinical symptoms (and age, sex, 
and MMSE) in a new random forest model, achieved an accuracy of 90.4% to discriminate 
between DLB and AD, compared to 88.7% based on the core feature alone. MTA was the third 
variable in terms of importance, after parkinsonism and visual hallucinations, but before 
cognitive fluctuations (Table 4). Thus, MTA marginally improved discrimination beyond that 
provided by the clinical features of DLB alone. In particular, MTA made a major contribution 
in atypical DLB cases without parkinsonism and visual hallucinations, where a normal MTA 
score was able to rule in most of the DLB patients with such a profile (9 out of 11 DLB patients). 
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Using the atrophy patterns instead of the visual rating scales revealed comparable results and 
highlighted the importance of the hippocampal-sparing pattern. This means that a normal MTA 
score is important, but in combination with abnormal PA and/or GCA-F scores it is even more 
important (Table 4). Similar results were obtained when these models were repeated by 
including education as extra predictive variable (data not shown). 
 
3.4 Association between visual rating scales and core clinical features in DLB 
Among DLB patients with clinical information available (n = 275), 77.2% had parkinsonism, 
58.5% had visual hallucinations, and 84.7% had cognitive fluctuations. For the following 
analyses, visual rating scores were dichotomized into normal (0) or abnormal (1) according to 
previously published cut-offs [21]. MTA was associated with a lower MMSE score (r=-0.145, 
p= 0.008). No significant associations were observed between GCA-F and PA and the MMSE 
score, nor for the three visual rating scales with any of the three DLB core clinical features (data 
not shown). 
 
All analyses were repeated including only those 94 DLB patients with abnormal DAT-scan. 
The results were similar to those in the total group, and several of them became more 
pronounced (data not shown). 
 
4 Discussion 
Establishing the signature pattern of brain atrophy in DLB has the potential to improve 
diagnosis, prediction of clinical course, and treatment response. The main novelty of this 
multicenter study is the first-time investigation of four distinct brain atrophy patterns in DLB 
patients, and its comparison with the distribution seen in AD. As a consequence, we have 
identified the signature atrophy pattern of DLB in the largest cohort reported to date. Although 
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we found widespread atrophy across medial temporal, frontal, and parietal lobes as compared 
to controls, DLB patients had less overall atrophy than the AD patients. In particular, DLB had 
less MTA than AD, but still showed PA and GCA-F atrophy, which indicates a higher 
frequency of the hippocampal-sparing pattern as compared to AD. Thus, the signature pattern 
of brain atrophy in DLB is hippocampal-sparing. Further, we also observed that MRI 
marginally improves the discrimination between DLB and AD over and above that of the core 
clinical features alone. In particular, MRI had greatest importance when discriminating atypical 
DLB cases without parkinsonism and visual hallucinations. 
 
Relative preservation of medial temporal lobe is listed as a “supportive biomarker” in the 
recently revised diagnostic criteria for DLB [18]. MTA alone could discriminate between DLB 
and AD with 64.7% accuracy, and contributed to the classification together with the core 
clinical features. However, a novel contribution of our study to the revised diagnostic criteria 
for DLB is that, indeed, lack of MTA is important, but more important is lack of MTA with the 
presence of atrophy in the posterior cortex (and/or the frontal cortex). This is by definition the 
hippocampal-sparing pattern. Thus, we suggest that relative preservation of medial temporal 
lobes concurrent with a marked PA and/or GCA-F supports the diagnosis of DLB, especially 
in cases showing inconsistent or absent core clinical features. The clinical utility of this finding 
should be explored in future studies and perhaps encourage a refinement of the MRI criteria in 
the current diagnostic criteria for DLB [18]. In particular, the clinical discrimination between 
DLB and AD patients with a hippocampal-sparing pattern needs to be further explored. 
 
The emergence of the hippocampal-sparing pattern in our study also aligns with another 
relevant functional biomarker of DLB, i.e. the cingulate island sign and occipital hypoperfusion 
on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). The cingulate island 
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sign reflects sparing of the posterior cingulate cortex relative to the precuneus and cuneus [34]. 
Combining MRI and FDG-PET findings could potentially increase the accuracy of DLB 
diagnosis.  
 
There is a remarkable pathological heterogeneity in DLB. Most DLB patients have some degree 
of AD pathology, which varies from sparse to severe [8]. MTA is associated with degree of tau 
pathology [35], thus more MTA can be seen as a proxy of AD [34]. This interpretation aligns 
with the data from Whitwell et al. [7], where 42% of the AD patients with a hippocampal-
sparing pattern had DLB pathology, while only 30% of those with a typical AD or a limbic-
predominant pattern had DLB pathology. Based on CSF analyses, AD pathology in DLB is 
associated with a more AD-like clinical phenotype [10], more rapid progression of dementia 
[36], and less response to cholinesterase inhibitors [9]. Thus, in addition to aiding in the 
differential diagnosis, the MRI atrophy pattern may provide information regarding the future 
rate of decline, which has been demonstrated in AD patients [5]. However, there are at present 
only few longitudinal DLB studies, with small samples. Thus, investigating AD pathology in 
DLB patterns of atrophy is warranted. 
 
We observed less overall structural atrophy in DLB compared to AD, with similar dementia 
severity. This suggests that functional brain changes, which are potentially reversible and 
amenable to drug therapy, may be more important in DLB compared to AD. For example, 
relatively more and earlier cholinergic deficits have been reported in DLB compared to AD 
[37], which could lead to better response to cholinergic agents [38].  
 
Relatively little is known about the underlying mechanisms of the core clinical features in DLB. 
We found no significant associations between regional atrophy and the core DLB features. 
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Previous studies conducted in smaller samples suggested that motor symptoms are associated 
with nigrostriatal pathology [39, 40]. A recent longitudinal study found that progression of 
parkinsonism was associated with greater whole brain atrophy as well as more hippocampus 
and amygdala atrophy [35]. In our study, MTA was significantly associated with cognitive 
impairment (i.e. lower MMSE score), consistent with previous studies [34]. Visual 
hallucinations have been found to be related to occipital pathology [41], but we did not observe 
any significant association between visual hallucinations and scores in the PA scale. However, 
although one of the criteria of the PA scale is widening of the parieto-occipital sulcus [30], and 
higher scores in the PA scale correlate with less gray matter in the occipital cortex [42], the PA 
scale was not designed to measure atrophy specifically in the occipital lobe. More detailed 
analyses including automated methods for image data processing and analysis, for example 
voxel-based morphometry or cortical thickness studies, may be needed to explore the structural 
brain-correlates of these clinical features. 
 
To our knowledge, this is the largest DLB cohort with MRI scans reported to date. The main 
limitation is the retrospective design, and thus, the diagnostic, clinical, and imaging procedures 
were not harmonized. To overcome the imaging issue, we applied visual rating scales of brain 
atrophy, performed by one rater across all centers, which are robust to variability in scanning 
parameters. Differences in age, sex, education, and MMSE scores were adjusted for throughout 
the statistical analyses. Diagnoses were mainly clinical, with only a subgroup having dopamine 
transporter SPECT and a minority with autopsy studies. Thus, some degree of misdiagnosis 
cannot be excluded, for example, with some DLB patients being diagnosed as AD and vice 
versa. However, these limitations often lead to increased noise, thus reducing the possibility to 
identify small effect sizes and associations. Consistent with this, findings were similar or even 
more pronounced in the DLB subgroup with abnormal DAT scan. Hence, the observed findings 
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in this large cohort are likely robust. However, to improve diagnostic accuracy, future studies 
should aim at including diagnostic markers highly specific for DLB, such as DAT scan, 
metaiodobenzylguanidine scan, and polysomnography [18], and aim towards including a 
substantial subgroup of patients with autopsy-confirmed diagnosis.  Visual rating scales are less 
sensitive than automated methods for image processing and analysis, and are subject to rater 
bias. For this reason, all the scans were rated by a single experienced rater who has previously 
demonstrated high reliability [5]. Furthermore, numerous previous studies have validated 
MTA, PA, and GCA-F against automated imaging methods [31, 42-44], including 
pathologically diagnosed dementia cases [45]. Visual rating scales are simple and quick [12, 
13, 21] and, thus, much more likely to be used in clinical practice, strengthening the real-world 
impact of our findings. Nonetheless, reliable ratings rely on experienced raters, which could 
limit the generalizability of this procedure to centers with less experienced raters. Finally, 
circularity cannot be excluded for MMSE and the core clinical features in this study. MRI was 
visually assessed in an unstructured manner as part of the diagnostic procedure, but is not a core 
feature of DLB and thus was not used for the diagnosis of DLB in this cohort. Since our focus 
was brain atrophy, this issue highlights the discriminative value of MRI when compared to the 
core clinical criteria. With the inclusion of biomarkers as part of the diagnostic criteria for both 
DLB and AD, there will always be a risk for circularity, as previously discussed [12, 51]. 
 
In conclusion, we have shown that DLB patients have widespread cortical atrophy, but 
compared to AD, DLB patients have less overall atrophy following a signature pattern 
consisting of a hippocampal-sparing type. Future studies should explore AD pathological 
comorbidity underlying these atrophy patterns in DLB, apply more detailed measurements of 
cortical and subcortical structures in large DLB cohorts, and explore their ability to predict key 
clinical features. 
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Alzheimer’s disease. However, a variety of atrophy patterns, including no atrophy, 
were observed in DLB.  
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structures in large DLB groups, and explore whether visual atrophy patterns can 
predict key clinical features including rate of cognitive decline. In addition, the 
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Figure 1. Correlation between age, sex, education, MMSE, and the visual rating 
scales in DLB. Weighted undirected graph with the edges showing the strength of the 
correlations (the thicker the edge, the higher the correlation coefficient). The size of 
the nodes represents the average weighted degree of each node, that is, the number of 
connections a node has with the rest of nodes (the larger the size, the larger number of 
connections). Modules are represented by colors: cluster 1 in salmon, including 
MMSE and education; cluster 2 in green, including age, sex, and the three visual 
rating scales (i.e. MTA, GCA-F and PA). 
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Figures revised
 Figure 2. Interaction between study group and visual rating scale (A), and 
overall degree of atrophy across groups (B). Age and sex were included as 
covariate variables. Light gray, NC; Dark gray, DLB; black, AD. DLB, dementia with 
Lewy bodies; AD, Alzheimer’s disease; NC, healthy controls; MTA, medial temporal 
atrophy scale; GCA-F, global frontal atrophy scale – frontal subscale; PA, posterior 
atrophy scale. 
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TABLES 
Table 1. Patient demographics 
 DLB 
(n = 333) 
AD 
(n = 352) 
NC 
(n = 233) 
DLB vs. NC 
p-value 
DLB vs. AD 
p-value 
AD vs. NC 
p-value 
Age 73.1 (8.2) 75.6 (7.5) 75.5 (5.5) 0.013 <0.001 0.411 
Sex, % female 38.4 51.1 47.6 0.468 <0.001 0.384 
Education, % high 38.4 63.5 90.5 <0.001 <0.001 0.004 
MMSE 22.3 (4.1) 22.9 (2.6) 29.2 (1.0) <0.001 0.061 <0.001 
Data are reported as mean(SD) for age and MMSE, and as percentage for sex and education. 
The variable years of education is coded as 0 (low education: less than 12 years of education) 
or 1 (high education: 12 years of education or more). The p-values reported in the table were 
obtained by conducting three separate paired logistic regression analyses for diagnosis (Y) 
and age, sex, education, and MMSE (predictors). The omnibus results of these three models 
are reported in the Appendix B. The sample size in these three models is 885 due to missing 
values in education. Virtually the same results are obtained in the whole sample (N = 918) 
when excluding education from the models (data not shown, the p-value in MMSE is 0.013 
when comparing DLB and AD). DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; 
NC, healthy controls; MMSE, Mini Mental State Examination.  
Tables revised
Table 2. Between-group differences in visual rating scales of brain atrophy 
 DLB AD NC DLB vs. NC DLB vs. AD AD vs. NC 
MTA, mean (SD) 1.49 (0.86) 2.1 (0.9) 0.9 (0.7) <0.001 <0.001 <0.001 
    Score 0, % 6.3 1.7 24.5    
    Score 1, % 41.7 21.3 51.5    
    Score 2, % 34.5 34.7 21.5    
    Score 3, % 13.2 31.0 2.6    
    Score 4, % 4.2 11.4 0    
GCA-F, mean (SD) 0.41 (0.60) 0.51 (0.65) 0.08 (0.27) <0.001 0.157 <0.001 
    Score 0, % 64.3 57.7 91.8    
    Score 1, % 30.0 33.8 8.2    
    Score 2, % 5.7 8.5 0    
    Score 3, % 0 0 0    
PA, mean (SD) 0.84 (0.82) 0.76 (0.80) 0.36 (0.64) <0.001 0.143 <0.001 
    Score 0, % 40.8 45.2 71.2    
    Score 1, % 36.6 34.4 22.3    
    Score 2, % 20.4 19.6 5.2    
    Score 3, % 2.1 0.9 1.3    
Overall atrophy, 
mean (SD) 0.79 (0.16) 0.94 (0.16) 0.36 (0.12) 
n.a. <0.001 n.a. 
    1st quartile 6.3 0.9 88.0    
    2nd quartile 42.3 17.3 12.0    
    3rd quartile 37.2 31.5 0.0    
    4th quartile 14.1 50.3 0.0    
Data are reported as mean(SD) for both MTA (continuous variable) and GCA-F and PA 
(ordinal variables), for simplicity. The models are conducted on these data and the 
frequency of the scores is also reported (in percentage). The p-values reported in the table 
for MTA, GCA-F, and PA were obtained by conducting multiple linear regression (MTA) or 
ordinal regression (GCA-F and PA, separately) models with the visual rating scales as Y 
variables, and diagnosis, age, and sex as predictors. Education and MMSE were also included 
as extra predictors in the sensitivity analysis. The omnibus results of these models are 
reported in the Appendix B. The p-values reported in the table for overall atrophy were 
obtained from the mixed ANCOVA. Only the post hoc paired comparison involving DLB vs. 
AD was of interest in the current study and is thus reported. Percentages for MTA scores are 
based on the highest score obtained in MTA (either side) only for this table. DLB, dementia 
with Lewy bodies; AD, Alzheimer’s disease; NC, healthy controls; n.a., non-applicable; MTA, 
medial temporal atrophy scale; GCA-F, global frontal atrophy scale – frontal subscale; PA, 
posterior atrophy scale.   
Table 3. Patterns of AD atrophy patterns in DLB, AD, and NC 
 DLB AD NC DLB vs. NC DLB vs. AD AD vs. NC 
Typical AD 28.8 50.0 4.3 <0.001 <0.001 <0.001 
Limbic-predominant 9.9 18.2 7.3 0.350 0.002 <0.001 
Hippocampal-sparing 39.3 19.0 26.2 0.002 <0.001 0.056 
Minimal-atrophy 21.9 12.8 62.2 <0.001 0.003 <0.001 
 <0.001 <0.001 <0.001    
Data are reported as percentage. All the p-values in this table were adjusted with the 
Hochberg’s correction for multiple testing. DLB, dementia with Lewy bodies; AD, Alzheimer’s 
disease; NC, healthy controls. 
  
Table 4. Using visual rating scales to discriminate between DLB and AD 
Model N Accuracy Sensitivity Specificity Variables contribution* 
MTA† 685 64.7 64.4 64.9 n.a. 
MTA, age, sex, MMSE 685 60.7 57.4 72.4 MTA, Imp = 37.6 
MMSE, Imp = 21.0 
age, Imp = 12.2 
sex, Imp = 7.0 
MTA, GCA-F, PA, age, sex, 
MMSE 
685 65.8 55.0 76.1 MTA, Imp = 118.2 
MMSE, Imp = 61.0 
age, Imp = 38.7 
sex, Imp = 32.0 
GCA-F, Imp = 4.2 
PK, VH, CF, age, sex, MMSE 291‡ 88.7 91.4 85.2 PK, Imp = 202.2 
VH, Imp = 109.0 
CF, Imp = 39.5 
MMSE, Imp = 21.2 
MTA, GCA-F, PA, PK, VH, CF, 
age, sex, MMSE 
291‡ 90.4 91.4 89.1 PK, Imp = 188.6 
VH, Imp = 100.8 
MTA, Imp = 49.1 
CF, Imp = 41.2 
MMSE, Imp = 21.1 
Atrophy patterns, age, sex, 
MMSE 
685 65.0 55.9 73.6 MMSE, Imp = 18.5 
H-S, Imp = 18.1 
Typ AD, Imp = 17.3 
L-P, Imp = 13.0 
M-A, Imp = 10.6 
age, Imp = 9.9 
sex, Imp = 6.3 
Atrophy patterns, PK, VH, CF, 
age, sex, MMSE 
291‡ 88.0 86.5 89.8 PK, Imp = 236.9 
VH, Imp = 115.7 
CF, Imp = 63.0 
H-S, Imp = 44.2 
MMSE, Imp = 21.1 
Age, Imp = 13.2 
Typ AD, Imp = 13.2 
*Variables that did not contributed to the model are not listed in the table;  
†Sensitivity was measured as the percentage of DLB patients with a normal MTA score, and 
specificity as the percentage of AD patients with an abnormal MTA score. 
‡Reduced N due to missing values in the DLB core clinical symptoms. n.a., non-applicable; 
MTA, medial temporal atrophy scale; GCA-F, global frontal atrophy scale – frontal subscale; 
PA, posterior atrophy scale; PK, parkinsonism; VH, visual hallucinations; CF, cognitive 
fluctuations; Typ AD, typical AD; H-S, hippocampal-sparing AD; L-P, limbic-predominant AD; 
M-A, minimal atrophy AD; Imp = importance of a given variable in the random forest, with 
higher values denoting greater predictive capacity. 
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